News

April 5, 2018

PHARMASCIENCE TO ENTER LEBANESE CARDIOVASCULAR MARKET

Pharmascience international will soon enter the Lebanese cardiovascular market with the launch of Rosuvastatin. Rosuvastatin is a drug that lowers bad cholesterol which reduces patients risk for heart attack, stroke, and other heart complications1.

Pharmascience international will soon enter the Lebanese cardiovascular market with the launch of Rosuvastatin. Rosuvastatin is a drug that lowers bad cholesterol which reduces patients risk for heart attack, stroke, and other heart complications1. Currently, Pharmascience’s presence in Lebanon is limited to drugs used to treat the Central Nervous System.

 

Cardiovascular treatment is a very competitive market. However, Pharmascience will be one of the first generic drugs on the Lebanese market. This drug will be priced cheaper than traditional branded ones, which will make it more accessible to patients undergoing cardiovascular issues.

 

Pharmascience is launching Rosuvastatin with Union Pharmaceutique d’Orient SAL (UPO), a Lebanese company that focuses on distributing and promoting high quality healthcare products2. Pharmascience and UPO have worked together for a long time which has fostered their strong relationship.

Pharmascience